Eflornithine Study 3b, NMTRC003B - ANBL0032

PRELIMINARY SCORE

CURATIVE

EFS

NON-CURATIVE

ADJUSTMENTS

Quality of life

Not qualified for an ESMO-MCBS credit

Serious and disabling adverse effects

Other adjustments

Eflornithine Study 3b, NMTRC003B - ANBL0032

SCORE

CURATIVE

A

Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE

Overall Survival

Progression-Free Survival

Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate

Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Brain Tumours
Therapeutic Indication: Eflornithine to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma (HRNB) who have demonstrated at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy. HRNB postimmunotherapy maintenance
Experimental Arm: Eflornithine
Control Arm: Popensity score matched external control from ANBL0032. Matched cohort 3:1